Health Technology · Pharmaceuticals: Major · NSE: VALIANTLAB · data 2026-10-09
Valiant Laboratories Ltd.
Health check: Average (5.9/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹119.8
Market cap
₹636 cr
P/E
40.6
P/B
—
ROE
-1.2%
ROCE
0.2%
Debt / equity
0.15
Dividend yield
0.00%
1-year return
46.5%
52-week high
₹132.25
52-week low
₹49.51
Operating margin
8.1%
Growth
| Revenue (last 12 months) | ₹306 cr |
| Net profit (last 12 months) | ₹16 cr |
| Sales growth, 3 years (yearly) | -10.7% |
| Profit growth, 3 years (yearly) | — |
Shareholding (2026-06-30)
| Promoters | 74.94% |
| Foreign institutions (FII) | 0.00% |
| Domestic institutions (DII) | 0.00% |
| Public | 25.06% |
| Promoter shares pledged | 0.00% |
| Number of shareholders | 14,341 |
Chart patterns
- Ascending triangle — forming (key level ₹132.25)
Similar companies
Anuh Pharma Limited (ANUHPHR) · Amanta Healthcare Limited (AMANTA) · Wanbury Limited (WANBURY) · Praveg Limited (PRAVEG) · Infinium Pharmachem Ltd. (INFINIUM)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open VALIANTLAB in NSE Scanner →